Mysterious Facts About LY2109761 Posted By Pros

Results from an analysis substantially extending previously published data (J Nucl Med. 2011; 52:1354�C60) are presented, that is, data from 479 follicular lymphoma patients are shown, whereas formerly, data from 271 patients were reported. Of the 479 individuals with follicular lymphoma, 219 had relapsed or refractory disease. For the whole cohort of follicular lymphoma patients (n?=?479), overall response to RIT was 84% (CR 67%, PR 17%). At the time of analysis, 73 patients had progressed and 43 individuals had died. For the subgroup of 220 refractory or relapsed follicular lymphoma patients, overall response after a median of three http://www.selleckchem.com/products/epz-5676.html prior therapies was 80% (CR 56%, PR 24%). Thirty-nine patients had progressed and 27 patients had died. For the whole group of follicular lymphoma patients, median overall survival has not been reached. In contrast, median overall survival for patients with refractory and relapsed disease http://www.selleckchem.com/products/ly2109761.html was 1280 days. Additional data on toxicity, time to progression, and overall survival will be presented. Conclusion: Data from the RIT network underscore the role of RIT as a safe and efficient treatment option for relapsed follicular lymphoma. 202 UPFRONT AUTOLOGOUS STEM-CELL TRANSPLANTATION IN TRANSFORMED INDOLENT NON-HODGKINS LYMPHOMA: AN OUTCOME ANALYSIS C. Madsen,1 M. B. Pedersen,1 E. K. Segel,1 K. Bendix,2 B. A. Jensen,3 P. Jensen,4 M. B. Moeller,5 P. Johansen,6 L. Munksgaard,7 P. D. Brown,8 F. A. D'Amore.1 1Department of Hemathology, Aarhus University Hospital, Aarhus, Denmark; 2Department of Pathology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Hemathology, Odense University Hospital, Odense, Denmark; 4Department of Hemathology, Aalborg University Hospital, Aalborg, Denmark; 5Department of Pathology, Odense University Hospital, Odense, Denmark; 6Department of Pathology, Aalborg University Hospital, Aalborg, Denmark; 7Department of Hemathology, Roskilde University Hospital, Roskilde, Denmark; 8Department of Hemathology, Rigshospitalet, Copenhagen Univesity Hospital, Copenhagen, Denmark. Introduction: When indolent non-Hodgkins lymphomas (IL) transform to a more aggressive histology (TRIL), the result is often a rapid clinical course and a shortened survival. The purpose of this study was to determine whether the outcome of these patients http://www.selleck.cn/products/Staurosporine.html improves if treated upfront with autologous stem-cell transplantation (ASCT) compared with rituximab-containing chemotherapy alone. Methods: Ninety-five patients (